Form 4: CervoMed Director Jane Hollingsworth Receives Stock Option

Director Jane Hollingsworth was granted an option to purchase 8,150 shares of CervoMed common stock following her election to the board.

Summary

• Jane H. Hollingsworth was granted 8,150 stock options to purchase common stock at an exercise price of $2.91 per share.
• The grant was issued on June 8, 2026, in connection with her election to the board of directors at the 2026 Annual Meeting of Stockholders.
• The options vest monthly over a one-year period in 1/12th increments, starting June 30, 2026, contingent on continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial strategy.

Positives

• Alignment of director interests with shareholders through equity-based compensation.

Negatives

• The grant results in minor potential dilution for existing shareholders.

Risks

• Vesting is subject to the director's continued service on the board.

Future Outlook

The options vest over a one-year period, incentivizing the director's continued service through June 2027.

Industry Context

StockSavvy.ai notes that this is a standard equity grant for a non-employee director following an annual meeting, consistent with typical corporate governance practices in the biotechnology sector.

Comparison to Industry Standards

• The grant follows standard non-employee director compensation policies common among small-cap biotech firms.
• The one-year vesting schedule is standard for annual director equity awards.

Corporate Governance

Stakeholder Impact

• Minor dilution impact on existing shareholders due to the issuance of new options.

Next Steps

• Monthly vesting of options beginning June 30, 2026.

Key Dates

Keywords

CervoMed, CRVO, Form 4, Director Compensation, Stock Options, Insider Transaction